MAPK3 and breast carcinoma: Studies on the prognostic impact of ERK1/2 expression in breast cancer have given contradictory results [59,63,64,65,66,67], with the larger series highlighting an association of ERK1/2 expression, especially nuclear phospho-ERK1/2, with good prognostic features and better outcome [63,64].